Emerging Interventions for Relapsed/Refractory Multiple Myeloma

Gareth Morgan, MD, PhD


November 24, 2021

For patients with multiple myeloma that is refractory to all three classes of therapies in the current standard of care, survival outcomes are poor and no clear treatment paradigm exists.

Dr Gareth Morgan, director of myeloma research at the Perlmutter Cancer Center at New York University, discusses advances in targeted and cellular therapies that are rapidly redefining treatment for patients with relapsed/refractory multiple myeloma.

Dr Morgan provides an update on the recent FDA approvals for relapsed/refractory multiple myeloma that are improving patient outcomes and explains the risks and benefits of emerging therapies that are currently being evaluated in clinical trials.

He also reports on the significant improvements in patient survival using such cellular therapies as chimeric antigen receptor T cells, bispecific T-cell engagers and targeted immunotherapies, including antibody-drug conjugates.

Looking forward, Dr Morgan points to the need to recognize and treat multiple myeloma as a biologically diverse disease of cellular subsets that need to be evaluated for optimal treatment in the upfront setting.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.